Effect of tirofiban-assisted endovascular intervention on neurological function in patients with acute ischemic stroke
Objective To investigate the effect of tirofiban-assisted endovascular intervention on neurological function in patients with acute ischemic stroke(AIS).Methods Eighty-six patients with AIS treated at Department of Intervention,Baoji City People's Hospital from January 2020 to October 2023 were selected for the randomized controlled trial.The patients were randomly divided into a control group and an observation group by the random number table method,with 43 cases in each group.There were 25 males and 18 females in the control group;they were(60.33±6.13)years old.There were 26 males and 17 females in the observation group;they were(59.48±5.29)years old.The control group took endovascular intervention;in addition,the observation group took tirofiban(treated for 2 weeks).The treatment efficacies,neurological function scores[National Institutes of Health Stroke Scale(NIHSS)and modified Rankin Scale(mRS)],neurotrophic indicators[brain-derived neurotrophic factor(BDNF),nerve growth factor(NGF),and serum CNS-specific protein(S100β)],platelet function markers(platelet aggregation,adhesion rates,and maximum aggregation time),and oxidative and inflammatory markers[glutathione peroxidase(GSH-Px),superoxide dismutase(SOD),malondialdehyde(MDA),and C-reactive protein(CRP)]were compared between the two groups by the independent sample t test and x2 test.Results After two weeks'treatment,the total effictive rate in the observation group higher than that in the control group[81.40％(35/43)vs.60.47％(26/43)],with a statistical difference between the two groups(x2=4.568,P＜0.05).The scores of NIHSS and mRS in the observation group were lower than those in the control group[(7.48±1.35)vs.(9.68±1.89)and(1.69±0.24)vs.(2.06±0.23)],with statistical differences(t=6.211 and 7.299;both P＜0.05).The levels of S100β,BDNF,and NGF in the observation group were better than those in the control group[(0.37±0.06)μg/L vs.(0.46±0.09)μg/L,(43.97±7.92)μg/L vs.(37.14±6.87)μg/L,and(99.38±12.73)ng/L vs.(86.47±9.56)ng/L],with statistical differences(t=5.456,4.272,and 5.318;all P＜0.05).The platelet aggregation rate,adhesion rate,and maximum aggregation time in the observation group were lower than those in the control group[(26.74±4.93)％vs.(32.64±5.26)％,(32.35±4.86)％vs.(38.26±5.38)％,and(147.35±21.83)s vs.(163.67±22.67)s],with statistical differences(t=5.367,5.345,and 3.400;all P＜0.05).The levels of GSH-Px,SOD,MDA,and CRP in the observation group were better than those in the control group[(168.97±24.73)U/L vs.(140.68±20.59)U/L,(86.36±12.79)U/mL vs.(75.21±11.47)U/mL,(4.89±1.35)μmol/Lvs.(6.82±1.63)μmol/L,and(9.36±3.25)mg/L vs.(12.18±4.75)mg/L],with statistical differences(t=5.765,4.256,5.980,and 3.213;all P＜0.05).There were no statistical differences in bleeding,symptomatic intracerebral hemorrhage,recurrence,and mortality between the two groups(all P＞0.05).Conclusion Tirofiban-assisted endovascular intervention for patients with AIS can significantly increase the overall treatment efficacy,their neurological function scores,and promote their neurological function recovery,and is safe.
TirofibanEndovascular interventionAcute ischemic strokeNeurological function
万方数据
维普
